Vice President, Head of Operations
Christopher Borella, Ph.D. is the vice president, head of operations at Silicon Therapeutics. Dr. Borella joined Silicon Therapeutics from Agios Pharmaceuticals where he was the head of early stage program management and the project leader for the MAT2A franchise.
During his eight years at Agios, Dr. Borella and his team were directly involved in bringing seven drug candidates, including two marketed drugs—Tibsovo® (ivosidenib) and Idhifa® (enasidenib)—forward into the clinic. Prior to Agios Therapeutics, Dr. Borella held project leadership positions at both Proteostasis and Synta Pharmaceuticals.
Dr. Borella earned a bachelor of science degree in chemistry from Rowan University in Glassboro, N.J. and doctor of philosophy degree in medicinal chemistry from Stony Brook University in Stony Brook, N.Y. and was a post-doctoral fellow at Memorial Sloan Kettering Cancer Center in New York.